Product: Progesterone Receptor Antibody
Catalog: AF6106
Description: Rabbit polyclonal antibody to Progesterone Receptor
Application: WB IHC IF/ICC
Reactivity: Human, Mouse, Rat, Monkey
Prediction: Pig, Rabbit, Dog
Mol.Wt.: 80~130kD; 99kD(Calculated).
Uniprot: P06401
RRID: AB_2834993

View similar products>>

   Size Price Inventory
 100ul $280 In stock
 200ul $350 In stock

Lead Time: Same day delivery

For pricing and ordering contact:
Local distributors

Product Info

Source:
Rabbit
Application:
WB 1:500-1:2000, IHC 1:50-1:200, IF/ICC 1:100-1:500
*The optimal dilutions should be determined by the end user.
*Tips:

WB: For western blot detection of denatured protein samples. IHC: For immunohistochemical detection of paraffin sections (IHC-p) or frozen sections (IHC-f) of tissue samples. IF/ICC: For immunofluorescence detection of cell samples. ELISA(peptide): For ELISA detection of antigenic peptide.

Reactivity:
Human,Mouse,Rat,Monkey
Prediction:
Pig(100%), Rabbit(83%), Dog(90%)
Clonality:
Polyclonal
Specificity:
Progesterone Receptor Antibody detects endogenous levels of total Progesterone Receptor.
RRID:
AB_2834993
Cite Format: Affinity Biosciences Cat# AF6106, RRID:AB_2834993.
Conjugate:
Unconjugated.
Purification:
The antiserum was purified by peptide affinity chromatography using SulfoLink™ Coupling Resin (Thermo Fisher Scientific).
Storage:
Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.
Alias:

Fold/Unfold

NR3C3; Nuclear receptor subfamily 3 group C member 3; PGR; PR; PRA; PRB; PRGR_HUMAN; Progesterone receptor; Progestin receptor form A; Progestin receptor form B;

Immunogens

Immunogen:
Uniprot:
Gene(ID):
Expression:
P06401 PRGR_HUMAN:

In reproductive tissues the expression of isoform A and isoform B varies as a consequence of developmental and hormonal status. Isoform A and isoform B are expressed in comparable levels in uterine glandular epithelium during the proliferative phase of the menstrual cycle. Expression of isoform B but not of isoform A persists in the glands during mid-secretory phase. In the stroma, isoform A is the predominant form throughout the cycle. Heterogeneous isoform expression between the glands of the endometrium basalis and functionalis is implying region-specific responses to hormonal stimuli.

Description:
Progesterone plays a central role in the reproductive events associated with the establishment and maintenance of pregnancy. Progesterone receptor, a member of the steroid receptor superfamily, mediates the physiologic effects of progesterone.
Sequence:
MTELKAKGPRAPHVAGGPPSPEVGSPLLCRPAAGPFPGSQTSDTLPEVSAIPISLDGLLFPRPCQGQDPSDEKTQDQQSLSDVEGAYSRAEATRGAGGSSSSPPEKDSGLLDSVLDTLLAPSGPGQSQPSPPACEVTSSWCLFGPELPEDPPAAPATQRVLSPLMSRSGCKVGDSSGTAAAHKVLPRGLSPARQLLLPASESPHWSGAPVKPSPQAAAVEVEEEDGSESEESAGPLLKGKPRALGGAAAGGGAAAVPPGAAAGGVALVPKEDSRFSAPRVALVEQDAPMAPGRSPLATTVMDFIHVPILPLNHALLAARTRQLLEDESYDGGAGAASAFAPPRSSPCASSTPVAVGDFPDCAYPPDAEPKDDAYPLYSDFQPPALKIKEEEEGAEASARSPRSYLVAGANPAAFPDFPLGPPPPLPPRATPSRPGEAAVTAAPASASVSSASSSGSTLECILYKAEGAPPQQGPFAPPPCKAPGASGCLLPRDGLPSTSASAAAAGAAPALYPALGLNGLPQLGYQAAVLKEGLPQVYPPYLNYLRPDSEASQSPQYSFESLPQKICLICGDEASGCHYGVLTCGSCKVFFKRAMEGQHNYLCAGRNDCIVDKIRRKNCPACRLRKCCQAGMVLGGRKFKKFNKVRVVRALDAVALPQPVGVPNESQALSQRFTFSPGQDIQLIPPLINLLMSIEPDVIYAGHDNTKPDTSSSLLTSLNQLGERQLLSVVKWSKSLPGFRNLHIDDQITLIQYSWMSLMVFGLGWRSYKHVSGQMLYFAPDLILNEQRMKESSFYSLCLTMWQIPQEFVKLQVSQEEFLCMKVLLLLNTIPLEGLRSQTQFEEMRSSYIRELIKAIGLRQKGVVSSSQRFYQLTKLLDNLHDLVKQLHLYCLNTFIQSRALSVEFPEMMSEVIAAQLPKILAGMVKPLLFHKK

Predictions

Predictions:

Score>80(red) has high confidence and is suggested to be used for WB detection. *The prediction model is mainly based on the alignment of immunogen sequences, the results are for reference only, not as the basis of quality assurance.

Species
Results
Score
Pig
100
Dog
90
Rabbit
83
Horse
0
Bovine
0
Sheep
0
Xenopus
0
Zebrafish
0
Chicken
0
Model Confidence:
High(score>80) Medium(80>score>50) Low(score<50) No confidence

PTMs - P06401 As Substrate

Site PTM Type Enzyme
K7 Sumoylation
S20 Phosphorylation P24941 (CDK2)
S25 Phosphorylation P24941 (CDK2)
S79 Phosphorylation
S81 Phosphorylation P68400 (CSNK2A1)
Y87 Phosphorylation
S88 Phosphorylation
S101 Phosphorylation
S102 Phosphorylation
S130 Phosphorylation
S162 Phosphorylation P24941 (CDK2)
K183 Acetylation
K183 Ubiquitination
S190 Phosphorylation P24941 (CDK2)
S213 Phosphorylation P24941 (CDK2)
S227 Phosphorylation
S294 Phosphorylation P24941 (CDK2) , P28482 (MAPK1) , P27361 (MAPK3)
S328 Phosphorylation
S345 Phosphorylation
K388 Sumoylation
K388 Ubiquitination
S397 Phosphorylation
S400 Phosphorylation P24941 (CDK2)
T430 Phosphorylation P24941 (CDK2)
K464 Methylation
K531 Sumoylation
S549 Phosphorylation
S552 Phosphorylation
S554 Phosphorylation P24941 (CDK2)
S558 Phosphorylation
S561 Phosphorylation
S666 Phosphorylation
S676 Phosphorylation P24941 (CDK2)
S735 Phosphorylation

Research Backgrounds

Function:

The steroid hormones and their receptors are involved in the regulation of eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues. Depending on the isoform, progesterone receptor functions as transcriptional activator or repressor.

Ligand-dependent transdominant repressor of steroid hormone receptor transcriptional activity including repression of its isoform B, MR and ER. Transrepressional activity may involve recruitment of corepressor NCOR2.

Transcriptional activator of several progesteron-dependent promoters in a variety of cell types. Involved in activation of SRC-dependent MAPK signaling on hormone stimulation.

Increases mitochondrial membrane potential and cellular respiration upon stimulation by progesterone.

PTMs:

Phosphorylated on multiple serine sites. Several of these sites are hormone-dependent. Phosphorylation on Ser-294 occurs preferentially on isoform B, is highly hormone-dependent and modulates ubiquitination and sumoylation on Lys-388. Phosphorylation on Ser-102 and Ser-345 also requires induction by hormone. Basal phosphorylation on Ser-81, Ser-162, Ser-190 and Ser-400 is increased in response to progesterone and can be phosphorylated in vitro by the CDK2-A1 complex. Increased levels of phosphorylation on Ser-400 also in the presence of EGF, heregulin, IGF, PMA and FBS. Phosphorylation at this site by CDK2 is ligand-independent, and increases nuclear translocation and transcriptional activity. Phosphorylation at Ser-162 and Ser-294, but not at Ser-190, is impaired during the G(2)/M phase of the cell cycle. Phosphorylation on Ser-345 by ERK1/2 MAPK is required for interaction with SP1.

Sumoylation is hormone-dependent and represses transcriptional activity. Sumoylation on all three sites is enhanced by PIAS3. Desumoylated by SENP1. Sumoylation on Lys-388, the main site of sumoylation, is repressed by ubiquitination on the same site, and modulated by phosphorylation at Ser-294.

Ubiquitination is hormone-dependent and represses sumoylation on the same site. Promoted by MAPK-mediated phosphorylation on Ser-294.

Palmitoylated by ZDHHC7 and ZDHHC21. Palmitoylation is required for plasma membrane targeting and for rapid intracellular signaling via ERK and AKT kinases and cAMP generation.

Subcellular Location:

Nucleus. Cytoplasm.
Note: Nucleoplasmic shuttling is both hormone- and cell cycle-dependent. On hormone stimulation, retained in the cytoplasm in the G(1) and G(2)/M phases.

Nucleus. Cytoplasm.
Note: Mainly nuclear.

Mitochondrion outer membrane.

Extracellular region or secreted Cytosol Plasma membrane Cytoskeleton Lysosome Endosome Peroxisome ER Golgi apparatus Nucleus Mitochondrion Manual annotation Automatic computational assertionSubcellular location
Tissue Specificity:

In reproductive tissues the expression of isoform A and isoform B varies as a consequence of developmental and hormonal status. Isoform A and isoform B are expressed in comparable levels in uterine glandular epithelium during the proliferative phase of the menstrual cycle. Expression of isoform B but not of isoform A persists in the glands during mid-secretory phase. In the stroma, isoform A is the predominant form throughout the cycle. Heterogeneous isoform expression between the glands of the endometrium basalis and functionalis is implying region-specific responses to hormonal stimuli.

Subunit Structure:

Interacts with SMARD1 and UNC45A. Interacts with CUEDC2; the interaction promotes ubiquitination, decreases sumoylation, and represses transcriptional activity. Interacts with PIAS3; the interaction promotes sumoylation of PR in a hormone-dependent manner, inhibits DNA-binding, and alters nuclear export. Interacts with SP1; the interaction requires ligand-induced phosphorylation on Ser-345 by ERK1/2 MAPK. Interacts with PRMT2. Isoform A interacts with NCOR2. Isoform B (but not isoform A) interacts with NCOA2 and NCOA1. Isoform B (but not isoform A) interacts with KLF9. Interacts with GTF2B.

Family&Domains:

Composed of three domains: a modulating N-terminal domain, a DNA-binding domain and a C-terminal ligand-binding domain.

Belongs to the nuclear hormone receptor family. NR3 subfamily.

Research Fields

· Cellular Processes > Cell growth and death > Oocyte meiosis.   (View pathway)

· Human Diseases > Cancers: Specific types > Breast cancer.   (View pathway)

· Organismal Systems > Endocrine system > Progesterone-mediated oocyte maturation.

· Organismal Systems > Endocrine system > Estrogen signaling pathway.   (View pathway)

References

1). SHP2 participates in decidualization by activating ERK to maintain normal nuclear localization of progesterone receptor. Reproduction [IF=3.8]

Application: IF/ICC    Species: Human    Sample:

Figure 4 RMC-4550 inhibits the nuclear translocation of PR and the expression of PR target genes in hESCs treated with P4. (A–B) Immunofluorescent staining of PR (red) in hESCs stimulated with P4 (2  μM) with or without RMC-4550 treatment for 1 h. Nuclei were stained with DAPI (blue). The number of nuclear PR cells from five different fields was counted and plotted as a histogram. Bar figures represent the ratios of nuclear PR. Scale bar = 50 µm; 10 μm (magnified graphs). (C–D) Immunofluorescent staining of PR (red) in hESCs, in which stimulated with P4 (2 μM) for 1 h, after transfection with sh-SHP2 or sh-Ctrl for 72 h. Nuclei were stained with DAPI (blue). The number of nuclear PR cells from five different fields was counted and plotted as a histogram. Bar figures represent the ratios of nuclear PR. Scale bar = 50 µm; 10 μm (magnified graphs). (E–H) Real-time PCR analysis of the transcriptional levels of the PR target genes HAND2, PLZF, HSD11B, and BMP2 in hESCs treated with or without P4 with or without RMC-4550. Error bars denote the s.d. (n = 3). Data were calibrated to the most highly expressing sample in blank control (yellow color).

2). An EMT-related genes signature as a prognostic biomarker for patients with endometrial cancer. BMC Cancer (PubMed: 37723477) [IF=3.8]

Application: WB    Species: Mouse    Sample:

FIGURE 2 PTS reduces reduction of NLRP3 inflammasome and apoptosis in DOX-treated mice. (A) WT C57/BL6J mice were pretreated with PTS (10 mg/kg) and afterwards with DOX (20 mg/kg cumulative dose) for 6 days. Immunochemistry staining of the liver sections with anti-NLRP3 (left, scale bar = 50 μm), the quantification of NLRP3 positive area in each group (right, n = 6); (B) qPCR analyses of NLRP3, IL-1β and IL-18 mRNA levels in each group (n = 6); (C) Western blot analyses of NLRP3, ASC, Caspase-1 p20, IL-1β, and IL-18 proteins and the quantification of the blots in each group (n = 4 per group); (D) Western blot analyses of Cleaved Caspase-3, BAX, and BCL-2 proteins (left) and quantification of the blots in each group (right, n = 4 per group).

3). Establishment of a New Cell Line of Canine Inflammatory Mammary Cancer: IMC‐118. Veterinary and Comparative Oncology (PubMed: 35429113) [IF=2.1]

Restrictive clause

 

Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.

For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.